TPP1 and juvenile neuronal ceroid lipofuscinosis: However, over the last several years a number of clinical trials have been initiated for some of the NCLs (NCT01399047, NCT01161576, NCT01414985, NCT01907087, NCT00151216, NCT00337636, NCT00028262, NCT01238315, NCT02725580; ClinicalTrials.gov; reviewed in [4]) and, more recently, the FDA approved the first treatment for CLN2-Batten disease, an enzyme replacement therapy called Brineura[5].